RecruitingPhase 1NCT07250087
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Studying Precursor T-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Rawan Faramand, MDMoffitt Cancer Center
- Intervention
- Asciminib(drug)
- Enrollment
- 36 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Moffitt Cancer Center, Tampa, Florida, United States
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07250087 on ClinicalTrials.govOther trials for Precursor T-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06976736A Long Term Follow-up Study of TScan TCR-T ProductsTScan Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07070323A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte MalignanciesBeijing GoBroad Hospital
- RECRUITINGPHASE2NCT06648889Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaGoethe University
- RECRUITINGEARLY PHASE1NCT06633341Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphomaZhejiang University
- RECRUITINGPHASE1NCT06326463CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT06220487A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLNanfang Hospital, Southern Medical University
- RECRUITINGPHASE2NCT07021677Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"Tata Memorial Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04778579Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapySara V. Latorre
See all trials for Precursor T-cell acute lymphoblastic leukemia →